PDS Biotechnology Corporation [NASDAQ: PDSB] gained 19.24% or 1.67 points to close at $10.35 with a heavy trading volume of 1971370 shares. The company report on May 24, 2021 that PDS Biotech to Host Company Conference Call Following Oral Presentation of PDS0101 Data at 2021 ASCO Annual Meeting.
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, announced that they will host a company conference call on June 8, 2021 at 8:00 am ET, following the oral presentation of preliminary data of PDS0101 at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. A press release summarizing the abstract data was issued on May 20.
During the call, PSD Biotech will review data from the previously announced oral presentation from the National Cancer Institute (NCI)-led phase 2 trial of PDS0101 in triple combination for the treatment of advanced HPV-associated cancers. Following the presentation, PDS Biotech will hold a question-and-answer session.
It opened the trading session at $8.4135, the shares rose to $10.60 and dropped to $8.4135, the range by which the price of stock traded the whole day. The daily chart for PDSB points out that the company has recorded 430.77% gains over the past six months. However, it is still -824.11% lower than its most recent low trading price.
If we look at the average trading volume of 2.00M shares, PDSB reached to a volume of 1971370 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about PDS Biotechnology Corporation [PDSB]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PDSB shares is $8.35 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PDSB stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for PDS Biotechnology Corporation shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 10, 2020. While these analysts kept the previous recommendation, Alliance Global Partners raised their target price to Buy. The new note on the price target was released on May 27, 2020, representing the official price target for PDS Biotechnology Corporation stock. Previously, the target price had yet another raise to $5.45, while Noble Capital Markets analysts kept a Outperform rating on PDSB stock.
The Average True Range (ATR) for PDS Biotechnology Corporation is set at 0.86 The Price to Book ratio for the last quarter was 9.50, with the Price to Cash per share for the same quarter was set at 1.29.
Trading performance analysis for PDSB stock
PDS Biotechnology Corporation [PDSB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 80.31. With this latest performance, PDSB shares gained by 84.82% in over the last four-week period, additionally plugging by 430.77% over the last 6 months – not to mention a rise of 751.85% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PDSB stock in for the last two-week period is set at 82.78, with the RSI for the last a single of trading hit 88.93, and the three-weeks RSI is set at 77.68 for PDS Biotechnology Corporation [PDSB]. The present Moving Average for the last 50 days of trading for this stock 5.47, while it was recorded at 8.68 for the last single week of trading, and 3.49 for the last 200 days.
PDS Biotechnology Corporation [PDSB]: A deeper dive into fundamental analysis
Return on Total Capital for PDSB is now -75.57, given the latest momentum, and Return on Invested Capital for the company is -75.53. Return on Equity for this stock declined to -76.48, with Return on Assets sitting at -65.43. When it comes to the capital structure of this company, PDS Biotechnology Corporation [PDSB] has a Total Debt to Total Equity ratio set at 2.25. Additionally, PDSB Total Debt to Total Capital is recorded at 2.20, with Total Debt to Total Assets ending up at 1.98. Long-Term Debt to Equity for the company is recorded at 1.81, with the Long-Term Debt to Total Capital now at 1.77.
Reflecting on the efficiency of the workforce at the company, PDS Biotechnology Corporation [PDSB] managed to generate an average of -$989,825 per employee.PDS Biotechnology Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 9.30 and a Current Ratio set at 9.30.
PDS Biotechnology Corporation [PDSB]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, PDS Biotechnology Corporation posted -0.19/share EPS, while the average EPS was predicted by analysts to be reported at -0.23/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 17.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PDSB.
An analysis of insider ownership at PDS Biotechnology Corporation [PDSB]
There are presently around $27 million, or 14.10% of PDSB stock, in the hands of institutional investors. The top three institutional holders of PDSB stocks are: VANGUARD GROUP INC with ownership of 860,990, which is approximately 20.581% of the company’s market cap and around 26.27% of the total institutional ownership; RENAISSANCE TECHNOLOGIES LLC, holding 667,747 shares of the stock with an approximate value of $5.8 million in PDSB stocks shares; and IKARIAN CAPITAL, LLC, currently with $3.33 million in PDSB stock with ownership of nearly New of the company’s market capitalization.
Positions in PDS Biotechnology Corporation stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 19 institutional holders increased their position in PDS Biotechnology Corporation [NASDAQ:PDSB] by around 797,430 shares. Additionally, 16 investors decreased positions by around 801,553 shares, while 5 investors held positions by with 1,542,209 shares. The mentioned changes placed institutional holdings at 3,141,192 shares, according to the latest SEC report filing. PDSB stock had 11 new institutional investments in for a total of 542,878 shares, while 9 institutional investors sold positions of 550,511 shares during the same period.